77202 20200117221626.0 sideral 110477 ART-2018-110477 eng Garcia-Azorin, D. Real-world preventative drug management of Chronic Migraine among Spanish Neurologists 2018 Access copy available to the general public Unrestricted O42 Background: In migraine, the therapeutic preventive drug arsenal is varied. Whenprescribing both Guidelines and patient characteristics are taken intoaccount. In Spain, the use of preventive therapies seems to beheterogeneous.The objective of this study was to evaluate real-life clinical prescribingpractice amongst neurologists in Spain Methods: Observational descriptive study done with a survey by Neurologistsof the Spanish Neurological Society (SEN). Neurologists who participatedwere divided into Headache Specialists or not. The followingdata was collected: socio-demographic data, ; preventive treatmentand choices different migraine sub-types, and their personal perceptionof efficacy and tolerability to different drugs. Results: We analyzed 152 surveys from neurologists around our country.From them: 43.4% were female, 53.3% <40 years, and 34.9% were interestedin headache .In regards to preventive treatment choice; in chronic migraine topiramate(57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereasin episodic migraine the preferred drugs were beta-blockers (47.7%), topiramate (21.5%) and amytriptiline (13.4%).Regarding perceived efficacy, topiramate was considered the bestoption in chronic migraine (42.7%) followed by onabotulinumtoxinA(25.5%) and amitryptiline (22.4%). In episodic migraine, neurologistpreferred topiramate (43.7%) and beta-blockers (30.3%).Regarding the duration of preventive therapy when improvementwas achieved, when treating episodic migraine 43.5% of the surveyedneurologists recommended 3 months and 39.5% preferred 6months. When they treated chronic migraine, 20.4% of neurologistsrecommended 3 months, 42.1% 6 months, 12.5% 9 months and22.4% preferred to maintain treatment during 12 months.When considering onabotulinumtoxinA treatment, the number ofprior therapeutical failures was cero in 7.2% of surveyed, one in5.9%, two in 44.1%, three in 30.9%, and four or more in 11.9%. Theincrease of OnabotulinumtoxinA dose up to 195 UI was consideredby 51% of neurologists after a first ineffective procedure, by 42.2% after two injections, and by 83% after a third infiltration. Surveyedcolleagues admitted to take into account in their decisions mainlypatient comorbidities (70.2%) rather than guidelines (13.9%). Conclusions: Initial management of Migraine among Spanish Neurologists is madewith the preventative drugs which are considered as first choices inmost of the guidelines. Management of episodic migraine differedfrom chronic migraine, both in the order or drugs and the perceptionof the most effective therapy. info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 3.918 2018 CLINICAL NEUROLOGY 46 / 199 = 0.231 2018 Q1 T1 NEUROSCIENCES 79 / 266 = 0.297 2018 Q2 T1 1.106 2018 Anesthesiology and Pain Medicine 2018 Q1 Neurology (clinical) 2018 Q1 Medicine (miscellaneous) 2018 Q1 info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/publishedVersion (orcid)0000-0001-5139-6031 Santos Lasaosa, S. Universidad de Zaragoza Gago-Veiga, A.B. Viguera Romero, J. Guerrero-Peral, A.L. Pozo-Rosich, P. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 19, Suppl. 1 (2018), O42 [1 pp] J. headache pain The Journal of headache and pain 1129-2369 https://thejournalofheadacheandpain.biomedcentral.com/track/pdf/10.1186/s10194-018-0900-0 Texto completo de la revista 73806 http://zaguan.unizar.es/record/77202/files/texto_completo.pdf Versión publicada 120732 http://zaguan.unizar.es/record/77202/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:77202 articulos driver 2020-01-17-21:57:13 ARTICLE